We are focused on the development of the next-generation of vaccination products targeting serious diseases, using our proprietary ImplaVax® solid dose formulation and needle-free delivery technology.

The ImplaVax® technology comprises three main components:

  • A single precision-engineered solid dose Universal Vaccine Implant (UVI) containing the monovalent or multivalent vaccine, antigen, or vector construct together with its associated excipient matrix that confers its mechanical strength and stability
  • A separate, disposable unit dose cassette pre-loaded with the single solid UVI
  • A handheld spring-powered actuator (single or reusable up to 1,000 times)

Our proprietary technologies are approved for human clinical trial use having successfully completed thorough feasibility tests.

Data delivered to date provide compelling evidence for the potential of ImplaVax® products to transform the performance and delivery of vaccines and make a significant positive impact on global healthcare.

You can watch the process of creating an ImplaVax® UVI and see the ImplaVax® in action here

Enesi’s ImplaVax® enabled products have potential to transform performance and delivery of vaccines